Related Experiment Video
Updated: Jul 6, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
SUMO modification of Huntingtin and Huntington's disease pathology
Joan S Steffan1, Namita Agrawal, Judit Pallos
1Department of Psychiatry and Human Behavior, Gillespie 2121, University of California, Irvine, CA 92697, USA.
Abstract:
Huntington's disease (HD) is characterized by the accumulation of a pathogenic protein, Huntingtin (Htt), that contains an abnormal polyglutamine expansion. Here, we report that a pathogenic fragment of Htt (Httex1p) can be modified either by small ubiquitin-like modifier (SUMO)-1 or by ubiquitin on identical lysine residues. In cultured cells, SUMOylation stabilizes Httex1p, reduces its ability to form aggregates, and promotes its capacity to repress transcription. In a Drosophila model of HD, SUMOylation of Httex1p exacerbates neurodegeneration, whereas ubiquitination of Httex1p abrogates neurodegeneration. Lysine mutations that prevent both SUMOylation and ubiquitination of Httex1p reduce HD pathology, indicating that the contribution of SUMOylation to HD pathology extends beyond preventing Htt ubiquitination and degradation.
More Related Videos
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Huntington Disease l: Introduction

